- Home
- NBBK vs ABVX Comparison
NBBK vs ABVX Comparison
Compare NBBK & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NBBK
- ABVX
- Stock Information
- Founded
- NBBK 1892
- ABVX 2013
- Country
- NBBK United States
- ABVX France
- Employees
- NBBK N/A
- ABVX N/A
- Industry
- NBBK
- ABVX
- Sector
- NBBK
- ABVX
- Exchange
- NBBK Nasdaq
- ABVX Nasdaq
- Market Cap
- NBBK 783.2M
- ABVX 722.3M
- IPO Year
- NBBK N/A
- ABVX N/A
- Fundamental
- Price
- NBBK $20.32
- ABVX $8.68
- Analyst Decision
- NBBK Buy
- ABVX Strong Buy
- Analyst Count
- NBBK 1
- ABVX 5
- Target Price
- NBBK $22.00
- ABVX $39.80
- AVG Volume (30 Days)
- NBBK 160.3K
- ABVX 89.5K
- Earning Date
- NBBK 10-30-2024
- ABVX 09-09-2024
- Dividend Yield
- NBBK N/A
- ABVX N/A
- EPS Growth
- NBBK N/A
- ABVX N/A
- EPS
- NBBK 0.30
- ABVX N/A
- Revenue
- NBBK $146,994,000.00
- ABVX $9,676,417.00
- Revenue This Year
- NBBK N/A
- ABVX $31.67
- Revenue Next Year
- NBBK N/A
- ABVX $1,189.66
- P/E Ratio
- NBBK $67.20
- ABVX N/A
- Revenue Growth
- NBBK 11.94
- ABVX 100.87
- 52 Week Low
- NBBK $13.10
- ABVX $8.69
- 52 Week High
- NBBK $20.98
- ABVX $17.02
- Technical
- Relative Strength Index (RSI)
- NBBK 58.58
- ABVX 26.00
- Support Level
- NBBK $19.51
- ABVX $10.27
- Resistance Level
- NBBK $20.97
- ABVX $10.79
- Average True Range (ATR)
- NBBK 0.54
- ABVX 0.36
- MACD
- NBBK -0.04
- ABVX -0.17
- Stochastic Oscillator
- NBBK 65.76
- ABVX 0.00
About NBBK NB Bancorp Inc.
NB Bancorp Inc operates as the holding company of Needham Bank. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in commercial real estate and multifamily loans, one- to four-family residential real estate loans, construction and land development loans, commercial and industrial loans, and consumer loans.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. They are evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two most common forms are UC and CD.